6:06 AM ET
8-K
Business Update
Cognition Therapeutics Business Update
Cognition Therapeutics has reached alignment with the FDA on the design of its planned Phase 3 registrational study for zervimesine (CT1812) in patients with dementia with Lewy bodies (DLB). The study will focus on mild-to-moderate DLB patients using hallucinations (NPI-2) as a primary endpoint and daily function (ADCS-ADL) as a secondary endpoint.
- Counterparty
- FDA
- Term
- 9 months